期刊
HUMAN IMMUNOLOGY
卷 75, 期 1, 页码 29-33出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2013.09.018
关键词
-
类别
资金
- National Natural Science Foundation of China [8132082, 81272685, 31301151, 81172355]
- Doctoral Fund of the Ministry of Education of China [20101202110002]
- Key Program of the Natural Science Foundation of Tianjin [09JCZDJC17100, 11 JCZDJC18400]
- Major Anticancer Technologies R & D Program of Tianjin [12ZCDZSY16700]
- Project of Tianjin Educational Commission [20100123]
IL-35 is a novel inhibitory cytokine that is mainly produced by regulatory T-cells (Tregs) and is required for Treg-mediated immunosuppression. However, the plasma levels of IL-35 in patients with pancreatic ductal adenocarcinoma (PDAC) have never been investigated. In this study, we found that plasma IL-35 levels more significantly increased in PDAC patients than in normal controls (134.53 +/- 92.45 pg/mL vs. 14.26 +/- 6.56 pg/mL). IL-35 mRNA levels were positively correlated with plasma IL-35 levels (EBI3, R = 0.925, p < 0.01; p35, R = 0.916, p < 0.01). Furthermore, IL-35 expression levels were associated with lymph node metastasis (p = 0.001) and late tumor stage (p = 0.002). For the resected patients, high IL-35 expression levels were associated with large tumor size (p < 0.01), higher TNM classification T staging (p < 0.05), and late tumor stage (p < 0.05). In conclusion, circulating IL-35 in PDAC patients significantly increased, suggesting that regulating the expression of IL-35 may provide a new possible target for the treatment of PDAC patients, especially for the resectable ones. (C) 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据